KnowTheStock
Log inCreate free account

Insulet Corporation

PODD
S&P 500Surgical and Medical Instrument Manufacturing · NASDAQ
$157.74last close · market cap 10.95 Billion
Compare with…
71.5SCORE / 100
Our verdictHOLDStrong Growth and ImprovingQtr Ending 2026-06-30 · trend positive

Why Hold

Income statement and balance sheet are strong; cash flow is moderate.

Next earnings: 2026-11-04 (BMO), EPS Forecast: $1.59

What is strong
  • Revenue Growth is 29.41%
  • Operating Income Growth is 26.64%
  • Net Income Growth is 58.96%
  • Earnings Per Share (EPS) Growth is 64.11%
  • Net Margin is 12.29%
  • Current Asset to Current Liability Ratio is 2.48
  • Current Debt to Net Income Ratio is 0.2
  • Total Debt to Total Assets Ratio is 0.31
What to watch
  • Debt Ratio is 0.55
  • Cash from Operations Growth is -0.95%
  • Capital Expenditure is High
  • Net Increase in Cash is Negative
  • Investment Risk is High

What changed

Score by quarter

Downgraded from Buy to Hold in the Mar 2025 quarter: 64.4 → 71.2 (+6.8). This quarter: +1.9.

4050607080Sep 2022Jun 2026

What the score is made of

Income statement81.5 +6.3
Balance sheet68.5 +0.0
Cash flow42.6 -10.3

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)3.05 Billion29.41 % growth
EPS5.3564.11 % growth
Profit margin12.29 %Profit per $1 of sales
P-E ratio—Not available
Market cap10.95 BillionShares × price
Debt-equity ratio0.68Leverage
Dividend0.00Per share, annual
Next earnings2026-11-04BMO · EPS forecast $1.59
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About Insulet Corporation

Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

CEO
Shacey Petrovic
Employees
2,600
Sector
Manufacturing
Exchange
NASDAQ
www.myomnipod.com

Similar stocks

Loading…